Loading...
Dernières publications
-
-
Lotta Plomp, Hortense Chassepot, Dimitri Psimaras, Thierry Maisonobe, Eric Mensi, et al.. Features of myositis and myasthenia gravis in patients treated with immune checkpoint inhibitors: a multicentric, retrospective cohort study. The Lancet Regional Health - Europe, 2025, 50, pp.101192. ⟨10.1016/j.lanepe.2024.101192⟩. ⟨hal-05404105⟩
-
Luce Barbat Du Closel, Nathalie Bonello-Palot, Yann Péréon, Andoni Echaniz-Laguna, Jean Philippe Camdessanche, et al.. Clinical and electrophysiological characteristics of women with X-linked Charcot-Marie-Tooth disease. European Journal of Neurology, 2023, 30 (10), pp.3265-3276. ⟨10.1111/ene.15937⟩. ⟨hal-04254200⟩
-
-
Joe-Elie Salem, Marie Bretagne, Baptiste Abbar, Sarah Leonard-Louis, Stéphane Ederhy, et al.. Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis. Cancer Discovery, 2023, 13 (5), pp.1100-1115. ⟨10.1158/2159-8290.CD-22-1180⟩. ⟨hal-04578810⟩
-
-
-
-
Corinna Preuße, Barbara Paesler, Christopher Nelke, Derya Cengiz, Thomas Müntefering, et al.. Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis. Acta Neuropathologica, 2022, 144 (2), pp.353-372. ⟨10.1007/s00401-022-02438-z⟩. ⟨hal-03830925⟩
-
Lee Nguyen, Marie Bretagne, Jennifer Arrondeau, Noel Zahr, Stephane Ederhy, et al.. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. Journal for Immunotherapy of Cancer, 2022, 10 (4), pp.e004699. ⟨10.1136/jitc-2022-004699⟩. ⟨hal-04002766⟩
Chiffres clés
130
Publications avec texte intégral
Open Access
55 %
Mots clés
Pharmacology
Aged
DM
Analyses multidimensionnelles
Autoimmune diseases
Female
Amyotrophy
Arthritis
Lysosomal storage diseases
Cancer
Auto-immunité
Antibody responses
Anticorps spécifique des myosites
Middle Aged
Interstitial lung disease
Biomarqueurs
Acute Kidney Injury/epidemiology/etiology
Adolescence
Biomarker
AAV vectors
Adeno-associated vector
IMNM
Inflammation
Amyotrophic lateral sclerosis
Inclusion body myositis
AAV antibody
Myocarditis
Interferon
Humans
Anti‐mitochondrial antibodies
Aldostérone
Abnormal movement
Idiopathic inflammatory myopathies
AAV
Auto-antibodies
Cytokines
Mass cytometry
Prognosis
AAV vector
Anti-MDA5
Immune checkpoint inhibitors
Anti-synthetase syndrome
Autoimmunity
Antibodies
Male
Fabry disease
Autoantibodies
Sphingosine-1-phosphate
Biomarkers
Myositis and muscle disease
Active
Aldosterone
IBM
Myosites
Adjudication
Muscle
Idiopathic inflammatory myopathy
Agalsidase
Polymyositis
Antisynthetase syndrome
Deep immune profiling
Outcome measures
Anti-drug antibodies
Machine learning
Animals
Anticorps anti-agalsidase
COVID-19
B-lymphocyte
Anti-Mi2
Anti-IgE IgG
Anti‐MDA5
Auto‐antibodies
Systems biology
Myositis
B cell homeostasis
Assisted communication devices
Dependovirus/genetics/immunology
Antisynthétase
Acetylcholine receptor antibodies
Cardio-oncology
Inborn errors of metabolism
Adverse drug reactions
Adeno-associated virus
Immunotherapy
Anti-interleukin-6
Autoantibody
Myopathy
Anti-MDA5 autoantibodies
Adult
Skeletal muscle
Anti-agalsidase antibodies
Inflammatory myopathy
Gene therapy
Antiphospholipid syndrome
Dermatomyositis
Acid-alpha-glucosidase
Anémie hémolytique
AAV humoral immunity
Antisynthetase
Adeno-associated virus vector